Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREW B GENTRY

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1922072560
CMS profile
503391
Location
BOZEMAN, MT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$603.61

24 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $603.61 24

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREW B GENTRY

NPI 1922072560 · CMS profile ID 503391

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

BOZEMAN, MT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922072560?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREW B GENTRY, NPI 1922072560, CMS profile ID 503391. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922072560?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ANDREW B GENTRY, NPI 1922072560, CMS profile ID 503391. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922072560?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ANDREW B GENTRY, NPI 1922072560, CMS profile ID 503391, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1922072560?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

24 matching records · $603.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 24 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–24 of 24.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $20.8812/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927175519 CMS
Boston Scientific Corporation $11.0211/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916553125 CMS
E.R. Squibb & Sons, L.L.C. $118.7511/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932741767 CMS
GENZYME CORPORATION $15.0211/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939142433 CMS
ABBVIE INC. $10.0011/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891018867 CMS
Regeneron Healthcare Solutions, Inc. $21.6710/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927175515 CMS
ABBVIE INC. $10.0010/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891018865 CMS
Boston Scientific Corporation $39.4210/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916553131 CMS
ABBVIE INC. $15.7309/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891018863 CMS
Boston Scientific Corporation $15.4508/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916553129 CMS
ABBVIE INC. $98.4006/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891018861 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.4506/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955641741 CMS
ABBVIE INC. $4.4105/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891018859 CMS
ABBVIE INC. $57.9104/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891018857 CMS
ABBVIE INC. $4.2504/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891018855 CMS
Boston Scientific Corporation $69.4504/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916553133 CMS
ABBVIE INC. $18.8003/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891018853 CMS
Boston Scientific Corporation $2.4303/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916553123 CMS
Boston Scientific Corporation $12.1603/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916553127 CMS
ABBVIE INC. $1.2403/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891018851 CMS
ABBVIE INC. $3.3303/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891018849 CMS
ABBVIE INC. $18.1102/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891018847 CMS
ABBVIE INC. $5.2101/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891018845 CMS
INTERCEPT PHARMACEUTICALS, INC. $13.5201/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951523933 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $393.23 22
PY2020 $142.24 6
PY2021 $293.32 9
PY2022 $603.61 24
PY2023 $273.73 14
PY2024 $414.03 15
PY2025 $613.07 28

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $154,413.55 9
PY2022 Principal investigator $564,732.27 36
PY2021 Recipient $140.50 1
PY2021 Principal investigator $488,808.99 57
PY2020 Principal investigator $877,751.94 34
PY2019 Recipient $410.95 1
PY2019 Principal investigator $141,659.45 56

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $8,135.40 12/21/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949774049
Principal investigator 1 PFIZER INC. $1,635.08 12/09/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949774219
Principal investigator 1 PFIZER INC. $7,072.70 10/26/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949796321
Principal investigator 1 PFIZER INC. $20,669.49 10/06/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949796815
Principal investigator 1 PFIZER INC. $14,632.50 10/01/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949796755
Principal investigator 1 PFIZER INC. $70,854.55 09/22/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949796323
Principal investigator 1 PFIZER INC. $356.53 08/17/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949802831
Principal investigator 1 PFIZER INC. $5,993.00 08/17/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949803339
Principal investigator 1 PFIZER INC. $14,617.88 08/04/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949804103
Principal investigator 1 PFIZER INC. $985.40 08/03/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949802977
Principal investigator 1 PFIZER INC. $4,846.42 07/20/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949806861
Principal investigator 1 PFIZER INC. $35,911.32 07/13/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949806863
Principal investigator 1 PFIZER INC. $24,440.41 06/30/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949811839
Principal investigator 1 PFIZER INC. $151,521.50 06/30/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949811899
Principal investigator 1 PFIZER INC. $3,504.48 06/03/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949811901
Principal investigator 1 PFIZER INC. $2,680.60 05/25/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949745751
Principal investigator 1 PFIZER INC. $32,924.51 05/21/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949745641
Principal investigator 1 PFIZER INC. $42,651.43 05/06/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949745651
Principal investigator 1 PFIZER INC. $1,340.30 05/03/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949745645
Principal investigator 1 PFIZER INC. $34,144.91 04/22/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949816871
Principal investigator 1 PFIZER INC. $1,340.30 04/19/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949817061
Principal investigator 1 PFIZER INC. $282.10 04/01/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949816869
Principal investigator 1 PFIZER INC. $2,278.26 03/31/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949825771
Principal investigator 1 PFIZER INC. $670.15 03/29/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949825555
Principal investigator 1 PFIZER INC. $60.00 03/23/2022 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949816829
Principal investigator 1 PFIZER INC. $2,379.00 03/23/2022 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949816861
Principal investigator 1 PFIZER INC. $24,571.30 03/23/2022 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949816863
Principal investigator 1 PFIZER INC. $1,500.00 03/23/2022 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949816865
Principal investigator 1 PFIZER INC. $21,381.00 03/23/2022 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949816879
Principal investigator 1 PFIZER INC. $750.00 03/23/2022 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949817063
Principal investigator 1 PFIZER INC. $14,772.95 03/03/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949825557
Principal investigator 1 PFIZER INC. $8,520.20 03/01/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949825553
Principal investigator 1 PFIZER INC. $2,776.80 02/04/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949827467
Principal investigator 1 PFIZER INC. $670.15 02/01/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949827525
Principal investigator 1 PFIZER INC. $2,010.45 01/25/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949828507
Principal investigator 1 PFIZER INC. $1,851.20 01/08/2022 Non-covered Recipient Entity
Bozeman Health Clinical Research
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949828505